4 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
Follow Left Ventricular Hypertrophy: new trials by email Literature Review of Left Ventricular Hypertrophy trials Research Report on Left Ventricular Hypertrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis ACE inhibitor Ramipril, non-RAS inhibitor antihypertensive therapy - Left Ventricular Hypertrophy, Hypertension | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 269 | 2009-05-01 | 2021-01-11 |
| The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 paricalcitol, placebo - Chronic Kidney Disease, Left Ventricular Hypertrophy | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 227 | 2008-02-01 | 2013-03-12 |
| Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo - Hypertension, Left Ventricular Hypertrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 460 | 2005-10-01 | 2011-05-26 |
| A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects. epoetin alfa - Anemia, Kidney Failure | Phase 3 | Completed | Janssen-Ortho Inc., Canada | 172 | 1997-12-01 | 2011-02-01 |
Hypertrophy, Left Ventricular (4) · Hypertension (2) · Anemia (1) · Overweight (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Cardiomegaly (4) · Cardiovascular Diseases (4) · Heart Diseases (4) · Hypertrophy (4) · Pathological Conditions, Anatomical (4) · Pathological Conditions, Signs and Symptoms (4) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Vascular Diseases (2) · Body Weight (1) · Chronic Disease (1)
Epoetin Alfa (1) · Losartan (1) · aliskiren (1) · paricalcitol (1)
AbbVie (prior sponsor, Abbott) (1) · Janssen-Ortho Inc., Canada (1) · Mario Negri Institute for Pharmacological Research (1) · Novartis Pharmaceuticals (1)
Italy (3) · Germany (2) · Russia (2) · Spain (2) · United States (2) · Argentina (1) · Australia (1) · Colombia (1) · Czechia (1) · Finland (1) · Poland (1) · Puerto Rico (1) · Romania (1) · Sweden (1) · Taiwan (1)
Ann Eldred, MD (1) · Piero Ruggenenti, MD (1)
PMID 16253719, PMID 18591942, PMID 21242674, PMID 21746765, PMID 22337679, PMID 23194491, PMID 33782036, PMID 40013543
2008 (1)